Skip to main content
Bio-3D printing startup HUAQING ZHIMEI has secured tens of millions of yuan in Series A funding to accelerate the clinical translation of regenerative treatments.
Funding
1 min read

Bio-3D printing startup HUAQING ZHIMEI has secured tens of millions of yuan in Series A funding to accelerate the clinical translation of regenerative treatments.

Huaqing Zhimei

Materials

Originally reported by 南极熊

Bio-3D printing startup HUAQING ZHIMEI has secured tens of millions of yuan in Series A funding to accelerate the clinical translation of regenerative treatments. This investment signals a critical move in the AM industry toward the high-precision fabrication of functional skin and dental grafts. By integrating exosome-loaded hydrogels with bioprinting technology, the company is pushing the sector beyond structural scaffolds into bioactive tissue repair. This funding facilitates the industrialization of personalized healthcare, bridging the gap between laboratory research and scalable clinical applications. 🧬🚀 #3DPrinting #Bioprinting #Funding #RegenerativeMedicine #MedTech

Explore Huaqing ZhimeiRead Original

How This Connects

6 related events
  1. Same pattern

    CollPlant has launched BioFlex, a ready-to-print rhCollagen kit optimized for high-resolution Digital Light Processing (DLP) 3D bioprinting.

  2. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  3. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  4. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  5. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  6. This article

    Bio-3D printing startup HUAQING ZHIMEI has secured tens of millions of yuan in Series A funding to accelerate the clinical translation of regenerative treatments.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.